Tyrosine Kinases / Adaptors
VEGF Receptor 2 Control Proteins
|
イイネ!(0)
|
|
| CSTコード |
包装 |
希望納入価格 (円) |
国内在庫  |
ご登録代理店情報  カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #2904S | 150 μL | 22,000 | |
|
VEGFR2抗体製品一覧
| 調製方法 | |
Nonphosphorylated VEGFR2 Cell Proteins: λ phosphatase 処理した昆虫細胞で発現させたヒトの組換えVEGFR2(Val789-Val1356)-GST 融合タンパク質 Phosphorylated VEGFR2 Cell Extracts: 未処理の昆虫細胞で発現させたヒトの組換えVEGFR2(Val789-Val1356)-GST 融合タンパク質 |
Western Blotting

Western blot analysis of recombinant human GST-VEGF Receptor 2 (Val789-Val1356), untreated or λ phosphatase-treated, using Phospho-VEGF Receptor 2 (Tyr1175) Antibody #2478 (upper), VEGF Receptor 2 Antibody #2479 (lower).
Vascular endothelial growth factor receptor 2 (VEGFR2, KDR, Flk-1) is a major receptor for VEGF-induced signaling in endothelial cells. Upon ligand binding, VEGFR2 undergoes autophosphorylation and becomes activated (1). Major autophosphorylation sites of VEGFR2 are located in the kinase insert domain (Tyr951/996) and in the tyrosine kinase catalytic domain (Tyr1054/1059) (2). Activation of the receptor leads to rapid recruitment of adaptor proteins, including Shc, Grb2, PI-3 kinase, Nck and the protein tyrosine phosphatases SHP-1 and SHP-2 (3). The phosphorylation of Tyr1212 provides a docking site for Grb2 binding and phospho-Tyr1175 binds with the p85 subunit of PI-3 kinase and PLCγ, as well as Shb (1,4,5). Signaling from VEGFR2 is necessary for the execution of VEGF-stimulated proliferation, chemotaxis and sprouting, as well as survival of cultured endothelial cells in vitro and angiogenesis in vivo (6-8).
-
Meyer, M. et al. (1999) EMBO J 18, 363-74.
-
Dougher-Vermazen, M. et al. (1994) Biochem Biophys Res Commun 205, 728-38.
-
Kroll, J. and Waltenberger, J. (1997) J Biol Chem 272, 32521-7.
-
Takahashi, T. et al. (2001) EMBO J 20, 2768-78.
-
Holmqvist, K. et al. (2004) J Biol Chem 279, 22267-75.
-
Karkkainen, M.J. and Petrova, T.V. (2000) Oncogene 19, 5598-605.
-
Rahimi, N. et al. (2000) J Biol Chem 275, 16986-92.
-
Claesson-Welsh, L. (2003) Biochem Soc Trans 31, 20-4.